---
title: Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say
url: https://www.nasdaq.com/articles/globus-medical-gmed-reports-q1-earnings-what-key-metrics-have-say
published_date: 2025-05-28T13:21:52.433355
collected_date: 2025-05-28T13:21:52.433413
source: Nasdaq
source_url: https://www.nasdaq.com
author: Zacks
description: For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter. The reported revenue represents a surprise of -4.81% over the Zacks Consensus Estimate of $628.32...
language: en
---

# Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say

*By Zacks*

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter. The reported revenue represents a surprise of -4.81% over the Zacks Consensus Estimate of $628.32...

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter. The reported revenue represents a surprise of -4.81% over the Zacks Consensus Estimate of $628.32 million. With the consensus EPS estimate being $0.74, the EPS surprise was -8.11%. 
 While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Globus Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenues- International: $114.26 million versus the three-analyst average estimate of $127.52 million. The reported number represents a year-over-year change of -7.7%. Geographic Revenues- United States: $483.86 million versus the three-analyst average estimate of $510.72 million. The reported number represents a year-over-year change of +0.2%. Net Sales by Product Category- Enabling Technologies: $22.19 million versus $38.79 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -30.6% change. Net Sales by Product Category- Musculoskeletal Solutions: $575.93 million versus $598.85 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.2% change. View all Key Company Metrics for Globus Medical here&gt;&gt;&gt; Shares of Globus Medical have returned -3.7% over the past month versus the Zacks S&amp;P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. 
7 Best Stocks for the Next 30 Days 
 
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." 
 
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.Â  See them now &gt;&gt; Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Globus Medical, Inc. (GMED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research 
 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.